Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Extended-release Guanfacine in European Subjects with ADHD
NCT01500694Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2012
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of guanfacine in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Started Mar 2012; status: completed.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01500694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01500694.